Atara Biotherapeutics, Inc.
ATRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,404% | -86.5% | 212.6% | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | 83.7% | -3.7% | 100% | -1,286.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -58.7% | -3,102.7% | -349.6% | -1,627.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -66.2% | -3,220.9% | -359.1% | -1,672.3% |
| EPS Diluted | -11.41 | -65.18 | -55.96 | -90.78 |
| % Growth | 82.5% | -16.5% | 38.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |